Neurocrine Biosciences to Highlight Innovations at May Investor Conferences

Neurocrine Biosciences Takes Center Stage at Upcoming Investor Conferences

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a biopharmaceutical company renowned for its focus on neuroscience, is gearing up for participation in two significant investor conferences in May 2025. The company's robust portfolio and clinical advancements will be highlighted during these events, showcasing its commitment to addressing pressing healthcare needs.

Conference Details

The first event, the BofA Securities 2025 Health Care Conference, is set for Tuesday, May 13, 2025, at 11:20 AM Pacific Time in the vibrant city of Las Vegas. The company’s Chief Executive Officer, Kyle Gano, along with Todd Tushla, the Vice-President of Investor Relations, will take the stage to present their latest innovations and therapeutic strategies.

Following this, on Tuesday, May 20, 2025, at 11:30 AM Eastern Time, Neurocrine's Chief Financial Officer, Matt Abernethy, and Chief Commercial Officer, Eric Benevich, will present at the RBCCM Global Healthcare Conference in New York. These platforms offer Neurocrine an opportunity to reach a wider audience of investors and stakeholders interested in the biopharmaceutical landscape.

Access to Presentations

Interested parties can tune into the live webcasts that will be accessible through Neurocrine's official website, specifically under the Investors section. For those unable to attend the live presentations, recordings of the webcasts will be available approximately one hour after the events conclude, remaining archived for about a month to allow for comprehensive review.

About Neurocrine Biosciences

With a mission centered on relieving suffering for patients confronted with complex medical conditions, Neurocrine Biosciences stands at the forefront of neuroscience-focused biopharmaceuticals. Over the course of three decades, the company has been dedicated to the discovery and development of transformative treatments tailored for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio encapsulates various FDA-approved therapies targeting conditions such as tardive dyskinesia, chorea linked to Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids.

In addition to its current offerings, Neurocrine boasts a promising pipeline packed with numerous compounds currently progressing through mid- to late-phase clinical development within their core therapeutic areas. By leveraging insights into the intricate connections between brain and bodily systems, the company continually strives to offer effective solutions for debilitating diseases and disorders.

For more detailed information about their latest projects and initiatives, stakeholders are encouraged to visit Neurocrine's website, and also follow the company’s updates on various social platforms like LinkedIn, X (formerly Twitter), and Facebook.

Neurocrine Biosciences aspires to be the benchmark in neuroscience, emphasizing that the pursuit of brave science is not just a slogan, but a heartfelt promise to patients seeking relief.

The NEUROCRINE BIOSCIENCES Logo Lockup and the slogan 'YOU DESERVE BRAVE SCIENCE' are registered trademarks of Neurocrine Biosciences, Inc.